Seattle-based Pauling.AI is shrinking early drug discovery timelines from six months to just a few w...
The AMW Read
The article introduces a new player in the Vertical AI-Bio segment using an agentic workflow and notes a high-profile talent move from Google Health, signaling the shift toward high-throughput 'Scientist-as-a-Service' models.
NoveltySignificance
Healthcare & Bio Β· Player MapTalent Dynamics
Seattle-based Pauling.AI is shrinking early drug discovery timelines from six months to just a few weeks. Led by former Google health director Javier Tordable, the platform uses autonomous AI agents to handle complex molecular modeling and toxicity predictions. This automation could potentially scale annual drug approvals from 40 to 400 by making the research of rare diseases economically feasible. The shift toward Scientist-as-a-Service models marks a systemic move from manual R&D to high-throughput discovery.
